Financials in USD. Standardized financial statements.
A compact view of how Jounce Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $82.00M | $26.91M | $62.34M | $147.87M | $65.20M | $71.64M | $37.20M | $0 | $0 |
| Revenue Growth? | +204.8% | -56.8% | -57.8% | +126.8% | -9.0% | +92.6% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $82.00M | $26.91M | $62.34M | $147.87M | $65.20M | $71.64M | $37.20M | $0 | $0 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% |
| Operating Expenses? | $134.24M | $117.96M | $107.46M | $95.06M | $96.50M | $90.86M | $51.66M | $30.40M | $16.21M |
| Operating Income? | -$52.24M | -$91.06M | -$45.12M | $52.82M | -$31.29M | -$19.21M | -$14.47M | -$30.40M | -$16.21M |
| EBITDA? | -$50.16M | -$91.06M | -$45.12M | $52.82M | -$23.50M | -$11.98M | -$11.76M | -$27.06M | -$9.41M |
| Income Before Tax | -$50.78M | -$90.86M | -$43.83M | $56.87M | -$27.33M | -$16.41M | -$13.70M | -$28.53M | -$10.52M |
| Income Tax Expense | $135,000 | $15,000 | $14,000 | $46,000 | $46,000 | $36,000 | $0 | $0 | $0 |
| Net Income? | -$50.92M | -$90.87M | -$43.84M | $56.82M | -$27.38M | -$16.44M | -$13.70M | -$28.53M | -$10.52M |
| EPS? | $-0.99 | $-1.82 | $-1.24 | $1.72 | $-0.84 | $-0.55 | $-0.45 | $-1.54 | $-0.48 |
| Diluted EPS? | $-0.99 | $-1.82 | $-1.24 | $1.66 | $-0.84 | $-0.55 | $-0.45 | $-1.54 | $-0.48 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality